Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban. apixaban. edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation. and those of injectable heparins for deep vein thrombosis prophylaxis. https://www.marketingjeunesse.com/product-category/leave-in-treatment-2/